

John O'donnell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/240423/publications.pdf>

Version: 2024-02-01

11
papers

440
citations

1163117

8
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

531
citing authors

#	ARTICLE	IF	CITATIONS
1	A randomized, double-blind, placebo-controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects. <i>Clinical and Translational Science</i> , 2021, 14, 1423-1430.	3.1	5
2	Rational design of a new antibiotic class for drug-resistant infections. <i>Nature</i> , 2021, 597, 698-702.	27.8	69
3	Thorough QT Study To Evaluate the Effect of Zoliflodacin, a Novel Therapeutic for Gonorrhea, on Cardiac Repolarization in Healthy Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0129221.	3.2	5
4	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β -Lactamases. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12511-12525.	6.4	44
5	Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β -Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282. <i>ACS Infectious Diseases</i> , 2020, 6, 1378-1388.	3.8	13
6	Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of <i>Neisseria gonorrhoeae</i> , Including Multi-Drug-Resistant Isolates. <i>ACS Infectious Diseases</i> , 2020, 6, 1332-1345.	3.8	73
7	Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β -Lactamase Inhibitor, in Healthy Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	11
8	Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	17
9	Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	15
10	ETX2514 is a broad-spectrum β -lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including <i>Acinetobacter baumannii</i> . <i>Nature Microbiology</i> , 2017, 2, 17104.	13.3	187
11	Human Pharmacokinetics and Dose Projection of ETX2514/Sulbactam Combination for Use in the Treatment of Infections Caused by <i>Acinetobacter baumannii</i> . <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	1